Cocrystal Pharma, Inc. (COCP), Thursday announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CDI-988 for the treatment and prophylaxis of norovirus infection.
The company believes that the designation further validates its unique structure-based drug discovery technology to design pan-viral antivirals that are effective new treatment options
Sam Lee, co-CEO of Cocrystal Pharma, commented, "Based on compelling data generated to date, we believe that CDI-988 has the potential to both prevent and treat norovirus infection.
In the pre-market hours, COCP is trading at $1.03, up 0.98 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.